Exploiting cell death pathways in regulatory T cells for cancer immunotherapy

Exploiting cell death pathways in regulatory T cells for cancer immunotherapy

Project details

Immunotherapies have revolutionised cancer therapy. Yet, despite clinical success, only a minority of patients treated show long-term clinical benefit and many malignancies remain to be targeted. Current immunotherapies block inhibitory pathways in tumour-resident T cells; however, interest in manipulating immune suppressive populations, such as FOXP3+ regulatory T (Treg) cells is growing.

This project will utilise unique pre-clinical models and patient cancer tissues to build on our discoveries targeting cell death processes in Treg cells and establish which cancers are best suited for a potential new immunotherapy. We will couple high-throughput single cell proteomics (CyTOF) and imaging approaches to uncover immune signatures that best predict responses.

Background work includes: Teh, et al Cell Death Differ.2020 27(7); Teh*, Robbins* et al Cell Death Differ.2020 doi: 10.1038/s41418-020-0585-1; Pierson et al., Nature Immunol. 2013 13(9).

About our research group

Our laboratory investigates how the molecular control of cell death processes shape immune cell homeostasis, function and malignancy. We have a particular interest in FOXP3+ regulatory T (Treg) cells, which govern many immune responses. Our recent discoveries point to critical distinctions in the regulation of cell survival processes in Treg cells, offering the possibility to control their function in inflammatory and cancer settings. 

 

Email supervisors

 

Researchers:

Associate Professor Daniel Gray

Associate Professor Daniel Gray
Associate Professor
Daniel
Gray
Joint Division Head
Charis Teh profile photo
Dr
Charis
Teh
Immunology division

Project Type: